LaFleur & Godfrey LLC reduced its position in Johnson & Johnson (NYSE:JNJ) by 1.5% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 77,474 shares of the company’s stock after selling 1,143 shares during the period. Johnson & Johnson comprises approximately 2.6% of LaFleur & Godfrey LLC’s portfolio, making the stock its 12th largest position. LaFleur & Godfrey LLC’s holdings in Johnson & Johnson were worth $9,152,000 at the end of the most recent reporting period.
Several other hedge funds also recently made changes to their positions in the company. Americafirst Capital Management LLC acquired a new position in Johnson & Johnson during the second quarter valued at $101,000. Tuttle Tactical Management LLC acquired a new position in Johnson & Johnson during the second quarter valued at $103,000. Lenox Wealth Management Inc. boosted its position in Johnson & Johnson by 24.3% in the second quarter. Lenox Wealth Management Inc. now owns 972 shares of the company’s stock valued at $118,000 after buying an additional 190 shares in the last quarter. Thomas J. Herzfeld Advisors Inc. boosted its position in Johnson & Johnson by 221.2% in the second quarter. Thomas J. Herzfeld Advisors Inc. now owns 1,002 shares of the company’s stock valued at $122,000 after buying an additional 690 shares in the last quarter. Finally, NCM Capital Management Group Inc. acquired a new position in Johnson & Johnson during the second quarter valued at $127,000. 64.13% of the stock is owned by institutional investors.
Johnson & Johnson (NYSE:JNJ) traded down 0.88% on Monday, hitting $113.13. The stock had a trading volume of 9,025,798 shares. The firm has a market capitalization of $307.77 billion, a price-to-earnings ratio of 19.86 and a beta of 0.75. The company’s 50 day moving average is $116.14 and its 200-day moving average is $118.35. Johnson & Johnson has a 1-year low of $94.28 and a 1-year high of $126.07.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, October 18th. The company reported $1.68 earnings per share for the quarter, beating analysts’ consensus estimates of $1.66 by $0.02. Johnson & Johnson had a net margin of 22.03% and a return on equity of 25.30%. The company earned $17.80 billion during the quarter, compared to the consensus estimate of $17.71 billion. During the same period in the previous year, the business earned $1.49 earnings per share. The firm’s quarterly revenue was up 4.2% on a year-over-year basis. On average, analysts forecast that Johnson & Johnson will post $6.72 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 6th. Investors of record on Tuesday, November 22nd will be paid a $0.80 dividend. This represents a $3.20 dividend on an annualized basis and a yield of 2.80%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $0.29. The ex-dividend date is Friday, November 18th. Johnson & Johnson’s dividend payout ratio (DPR) is 56.64%.
JNJ has been the subject of several research analyst reports. Vetr raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $124.21 price objective for the company in a research report on Monday, August 22nd. Zacks Investment Research raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $139.00 price objective for the company in a research report on Friday, August 5th. BTIG Research reissued a “neutral” rating on shares of Johnson & Johnson in a research report on Wednesday, September 7th. RBC Capital Markets set a $133.00 price target on Johnson & Johnson and gave the company a “buy” rating in a research note on Wednesday, November 9th. Finally, Credit Suisse Group AG restated a “neutral” rating and set a $123.00 price target on shares of Johnson & Johnson in a research note on Monday, September 19th. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating and nine have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $121.02.
In other news, Director Charles Prince acquired 875 shares of the firm’s stock in a transaction that occurred on Friday, October 21st. The shares were acquired at an average cost of $114.11 per share, with a total value of $99,846.25. Following the completion of the purchase, the director now directly owns 26,520 shares of the company’s stock, valued at approximately $3,026,197.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.11% of the stock is currently owned by corporate insiders.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.